Market Closed -
Nasdaq
16:30:00 2024-05-03 EDT
|
5-day change
|
1st Jan Change
|
15.35
USD
|
+1.66%
|
|
+5.64%
|
-18.35%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
391.2
|
1,632
|
872.1
|
467.6
|
1,356
|
1,224
|
-
|
-
|
Enterprise Value (EV)
1 |
391.2
|
1,497
|
709.3
|
414
|
1,356
|
952
|
825.8
|
811.7
|
P/E ratio
|
-7.12
x
|
-17.3
x
|
-6.92
x
|
-4
x
|
-9.45
x
|
-7.57
x
|
-8.2
x
|
-14.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
19.1
x
|
106
x
|
46.3
x
|
14.1
x
|
-
|
-
|
42.6
x
|
8.67
x
|
EV / Revenue
|
19.1
x
|
97.2
x
|
37.7
x
|
12.5
x
|
-
|
-
|
28.8
x
|
5.75
x
|
EV / EBITDA
|
-
|
-17,529,769
x
|
-5,571,747
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-5.99
x
|
-23.3
x
|
-5.37
x
|
-3.1
x
|
-
|
-5.18
x
|
-4.83
x
|
-10.3
x
|
FCF Yield
|
-16.7%
|
-4.3%
|
-18.6%
|
-32.3%
|
-
|
-19.3%
|
-20.7%
|
-9.75%
|
Price to Book
|
-
|
6.36
x
|
5.3
x
|
2.07
x
|
-
|
5.94
x
|
4.81
x
|
5.03
x
|
Nbr of stocks (in thousands)
|
29,678
|
33,639
|
35,108
|
51,663
|
72,143
|
79,754
|
-
|
-
|
Reference price
2 |
13.18
|
48.53
|
24.84
|
9.050
|
18.80
|
15.35
|
15.35
|
15.35
|
Announcement Date
|
20-03-12
|
21-03-09
|
22-03-07
|
23-03-07
|
24-03-19
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
20.49
|
15.4
|
18.82
|
33.19
|
-
|
-
|
28.71
|
141.2
|
EBITDA
|
-
|
-85.39
|
-127.3
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-54.54
|
-86.88
|
-129.9
|
-134.4
|
-171.3
|
-200
|
-206.9
|
-122.3
|
Operating Margin
|
-266.16%
|
-564.03%
|
-690.48%
|
-404.81%
|
-
|
-
|
-720.72%
|
-86.58%
|
Earnings before Tax (EBT)
1 |
-51
|
-86.48
|
-131.8
|
-134.5
|
-165.8
|
-196.3
|
-197.6
|
-130.5
|
Net income
1 |
-51
|
-86.48
|
-131.8
|
-134.5
|
-165.8
|
-195.6
|
-199.2
|
-116.9
|
Net margin
|
-248.88%
|
-561.47%
|
-700.46%
|
-405.21%
|
-
|
-
|
-693.74%
|
-82.74%
|
EPS
2 |
-1.850
|
-2.810
|
-3.590
|
-2.260
|
-1.990
|
-2.029
|
-1.872
|
-1.087
|
Free Cash Flow
1 |
-65.34
|
-64.36
|
-132
|
-133.8
|
-
|
-183.9
|
-171.2
|
-79.15
|
FCF margin
|
-318.87%
|
-417.83%
|
-701.73%
|
-402.97%
|
-
|
-
|
-596.2%
|
-56.04%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-12
|
21-03-09
|
22-03-07
|
23-03-07
|
24-03-19
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
5.464
|
4.049
|
33.19
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-38.35
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-37.08
|
-35.36
|
-6.933
|
-43.15
|
-43.86
|
-40.43
|
-40.51
|
-39.08
|
-43.67
|
-48.03
|
-47.74
|
-48.65
|
-50
|
-51.51
|
-60.03
|
Operating Margin
|
-678.57%
|
-873.4%
|
-20.89%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-37.51
|
-35.91
|
-7.95
|
-44
|
-43.3
|
-39.26
|
-39.38
|
-37.92
|
-42.36
|
-46.13
|
-47.14
|
-48.17
|
-49.64
|
-51.34
|
-55.75
|
Net income
1 |
-37.51
|
-35.91
|
-7.95
|
-44
|
-43.3
|
-39.26
|
-39.38
|
-37.92
|
-42.36
|
-46.13
|
-47.01
|
-48.05
|
-49.52
|
-51.09
|
-55.75
|
Net margin
|
-686.44%
|
-886.98%
|
-23.95%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.020
|
-0.9700
|
-0.2100
|
-1.060
|
-0.5500
|
-0.4600
|
-0.4900
|
-0.4700
|
-0.5300
|
-0.5000
|
-0.5147
|
-0.5112
|
-0.5178
|
-0.5013
|
-0.5400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-09
|
22-03-07
|
22-05-16
|
22-08-08
|
22-11-14
|
23-03-07
|
23-05-09
|
23-08-09
|
23-11-07
|
24-03-19
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
136
|
163
|
53.5
|
-
|
272
|
398
|
413
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-65.3
|
-64.4
|
-132
|
-134
|
-
|
-184
|
-171
|
-79.2
|
ROE (net income / shareholders' equity)
|
-
|
-46.3%
|
-60.9%
|
-62.2%
|
-
|
-76%
|
-70.1%
|
-9%
|
ROA (Net income/ Total Assets)
|
-
|
-29.6%
|
-38.1%
|
-40.6%
|
-
|
-55.8%
|
-54.1%
|
-7.24%
|
Assets
1 |
-
|
292.3
|
346.4
|
331.3
|
-
|
350.4
|
368.2
|
1,614
|
Book Value Per Share
2 |
-
|
7.640
|
4.690
|
4.370
|
-
|
2.580
|
3.190
|
3.050
|
Cash Flow per Share
|
-
|
-1.960
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
4.09
|
5.25
|
1.06
|
-
|
6.13
|
7.78
|
12.8
|
Capex / Sales
|
-
|
26.54%
|
27.89%
|
3.21%
|
-
|
-
|
27.08%
|
9.09%
|
Announcement Date
|
20-03-12
|
21-03-09
|
22-03-07
|
23-03-07
|
24-03-19
|
-
|
-
|
-
|
Last Close Price
15.35
USD Average target price
26.25
USD Spread / Average Target +71.01% Consensus |
1st Jan change
|
Capi.
|
---|
| -18.35% | 1.2B | | -1.43% | 103B | | +8.96% | 101B | | +4.40% | 23.07B | | -12.15% | 22.23B | | -4.36% | 18.05B | | -39.98% | 17.18B | | -10.04% | 16.94B | | +6.79% | 14.07B | | +38.61% | 12.35B |
Bio Therapeutic Drugs
|